Q4 2024 Earnings Forecast for Viking Therapeutics, Inc. (NASDAQ:VKTX) Issued By Leerink Partnrs

Viking Therapeutics, Inc. (NASDAQ:VKTX) – Stock analysts at Leerink Partnrs lifted their Q4 2024 EPS estimates for Viking Therapeutics in a report released on Wednesday, April 24th. Leerink Partnrs analyst T. Smith now expects that the biotechnology company will post earnings per share of ($0.25) for the quarter, up from their previous forecast of ($0.26). The consensus estimate for Viking Therapeutics’ current full-year earnings is ($1.05) per share. Leerink Partnrs also issued estimates for Viking Therapeutics’ FY2025 earnings at ($1.64) EPS, FY2026 earnings at ($2.37) EPS, FY2027 earnings at ($3.46) EPS and FY2028 earnings at ($1.19) EPS.

A number of other research firms have also commented on VKTX. William Blair restated an “outperform” rating on shares of Viking Therapeutics in a research report on Friday, February 23rd. Stifel Nicolaus reiterated a “buy” rating and set a $80.00 target price on shares of Viking Therapeutics in a research report on Friday, March 15th. BTIG Research lifted their target price on shares of Viking Therapeutics from $100.00 to $125.00 and gave the company a “buy” rating in a research report on Tuesday, March 26th. StockNews.com upgraded shares of Viking Therapeutics to a “sell” rating in a research report on Thursday. Finally, Oppenheimer lifted their price target on shares of Viking Therapeutics from $116.00 to $138.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 26th. One analyst has rated the stock with a sell rating and ten have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $112.25.

Viking Therapeutics Stock Up 7.9 %

VKTX opened at $74.31 on Monday. The firm has a 50-day moving average price of $69.11 and a 200-day moving average price of $35.56. Viking Therapeutics has a twelve month low of $8.28 and a twelve month high of $99.41. The company has a market capitalization of $8.19 billion, a price-to-earnings ratio of -79.90 and a beta of 1.05.

Viking Therapeutics (NASDAQ:VKTX) last posted its earnings results on Wednesday, April 24th. The biotechnology company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.01. During the same quarter in the previous year, the company posted ($0.25) earnings per share.

Institutional Trading of Viking Therapeutics

A number of hedge funds have recently modified their holdings of the business. Vanguard Group Inc. boosted its stake in Viking Therapeutics by 1.8% in the 4th quarter. Vanguard Group Inc. now owns 5,381,904 shares of the biotechnology company’s stock worth $100,157,000 after purchasing an additional 97,552 shares in the last quarter. American Century Companies Inc. boosted its stake in Viking Therapeutics by 59.6% in the 3rd quarter. American Century Companies Inc. now owns 2,202,228 shares of the biotechnology company’s stock worth $24,379,000 after purchasing an additional 822,156 shares in the last quarter. Deerfield Management Company L.P. Series C boosted its stake in Viking Therapeutics by 13.7% in the 3rd quarter. Deerfield Management Company L.P. Series C now owns 1,279,000 shares of the biotechnology company’s stock worth $14,159,000 after purchasing an additional 154,000 shares in the last quarter. Wasatch Advisors LP boosted its stake in Viking Therapeutics by 32.4% in the 4th quarter. Wasatch Advisors LP now owns 1,274,945 shares of the biotechnology company’s stock worth $23,727,000 after purchasing an additional 311,681 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its stake in Viking Therapeutics by 88.3% in the 4th quarter. Goldman Sachs Group Inc. now owns 1,119,885 shares of the biotechnology company’s stock worth $20,841,000 after purchasing an additional 525,296 shares in the last quarter. Institutional investors own 76.03% of the company’s stock.

Insider Buying and Selling

In other Viking Therapeutics news, CEO Brian Lian sold 35,000 shares of the business’s stock in a transaction on Tuesday, January 30th. The shares were sold at an average price of $23.95, for a total transaction of $838,250.00. Following the transaction, the chief executive officer now directly owns 2,264,882 shares of the company’s stock, valued at approximately $54,243,923.90. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, CEO Brian Lian sold 35,000 shares of the business’s stock in a transaction on Tuesday, January 30th. The shares were sold at an average price of $23.95, for a total transaction of $838,250.00. Following the sale, the chief executive officer now owns 2,264,882 shares in the company, valued at approximately $54,243,923.90. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Sarah Kathryn Rouan sold 25,000 shares of the business’s stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $28.05, for a total transaction of $701,250.00. The disclosure for this sale can be found here. Insiders have sold a total of 329,079 shares of company stock valued at $8,769,653 over the last three months. 4.70% of the stock is owned by company insiders.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.